CARLSBAD, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced preliminary […]
The AcQForce Flutter clinical study was submitted to the FDA as part of Acutus’ PMA submission for the AcQBlate Force Sensing Ablation Catheter […]
Drug Candidate, CQ-001 (cannabidiol “CBD” + IP formula), also demonstrated substantially reduced seizures at higher doses, with less CBD, compared to standard CBD.
[…]
Interview update with Larry Heaton, CEO and President […]
XRX-OXY-101 Study will inform the dose choice in the upcoming Phase 3 Clinical Trial […]
Acutus Medical, Inc’s (NASDAQ: AFIB) CEO David Roman recently spoke with Wall Street Analyzer to provide an overview of the company, discuss recent news, and go over key goals for the next 6-8 months. The company is focused on the treatment of atrial fibrillation and other cardiac arrhythmias and has a novel mapping system that enables physicians to visualize disease on a patient by patient basis and therefore has a higher success rate than current standard of care procedures. Mr. Roman went over AFIB’s recent Q3 results that included an over 50% increase in their international procedures and a 17% year to year growth in overall procedures. Perhaps the biggest announcement was the company’s deal with Medtronic for sale of their access portfolio, referred to as Left Heart Access (LHA), and consists of uncapped revenue based earn-outs for four years after the official launch. Acutus Medical produced $17.3 million in revenue in 2021. […]
ANN ARBOR, MI / ACCESSWIRE / November 14, 2022 / Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or the “Company”, a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, reported consolidated financial results for […]
VANCOUVER, BC, Nov. 8, 2022 /CNW/ – Scottie Resources Corp. (“Scottie” or the “Company“) (TSXV: SCOT) (OTCQB: SCTSF) (FSE: SR8) is pleased to report new assays on its Blueberry Contact Zone including an intercept of 20.3 g/t gold […]
IRVINE, CA / ACCESSWIRE / November 3, 2022 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2023 first quarter ended September 30, 2022. The Company also filed its Quarterly Report on Form 10-Q […]
Public Safety Innovator Accelerates Growth Nationwide […]
Copyright © 2019 The Wall Street Analyst, LLC. All rights reserved. Website by MyWebsiteSpot.com